What are the main indications of Seleniso?

Selinexor is a new type of anti-cancer targeted drug with a unique mechanism of action. It mainly interferes with the survival path of cancer cells by inhibiting the nuclear export protein XPO1. The XPO1 protein is highly expressed in a variety of malignant tumors. It mediates the transport of tumor suppressor proteins such as p53 and BRCA1 from the nucleus to the cytoplasm, leading to the functional inactivation of these key proteins. By inhibiting XPO1, selinesol is able to retain these tumor suppressor factors in the nucleus, promote apoptosis of cancer cells and inhibit their proliferation.

Currently, one of the main indications for selinesol is relapsed or refractory multiple myeloma, especially for patients whose disease has progressed after receiving multiple treatment options (such as proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibodies, etc.). Its use in such refractory patients provides new treatment options for those who are ineffective with traditional treatments. Selinisol is usually used in this indication in combination with dexamethasone or other anti-myeloma drugs, showing controllable efficacy and safety.

In addition to multiple myeloma, selinesol has also been approved by the U.S. FDAfor the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including patients transformed from follicular lymphoma. Such patients often lack effective targeted drugs after multiple lines of treatment, and selinesol provides a new option with a unique mechanism and non-cross-resistance. Studies have also shown that the drug has certain activity in different subtypes of B-cell lymphoma, especially for older patients who cannot tolerate high-intensity chemotherapy.

In addition to its approved indications, selinesol is currently undergoing clinical studies in other solid tumors and hematological tumors, including pancreatic cancer, brain glioma, ovarian cancer, etc. Although these indications are still in the experimental stage, their unique mechanisms provide new hope for patients with strong drug resistance and limited treatment options.

Reference materials:https://www.selincro.com/